Good morning Ladies and Gentlemen,
The Company embarked upon a bold strategy over the last 2 years including the transition of its manufacturing base to the United States and a full review of its product offering. This was necessary in order to obtain full FDA and regulatory compliance as well as progressing the Company’s drive into research and development initiatives for new and improved products being demanded by an evolving healthcare industry. (Read more in Official Release)
For further information, please contact:
Mr Jason D’Arcy
Company Secretary
Telephone AUS: +614 1767 7732
Telephone US: +1 214 930 2233
Email: jason.darcy@azurehealthcare.com.au
